Isola Capital Group
Isola Capital Group is a family office asset management platform based in Hong Kong, with an additional office in Belgium. Founded in 1946, the firm focuses on entrepreneurial and multi-asset class investments, including private equity, venture capital, and private credit. It specializes in mezzanine financing, pre-IPO investments, and various other financial instruments. Isola Capital Group operates through two main divisions: Isola Capital Partners, which targets direct investments in the Asia Pacific region, particularly in sectors such as education, healthcare, and premium consumer goods; and Isola Venture Partners, which invests globally in early-stage ventures across industries like EdTech, FinTech, and HealthTech. The firm aims to acquire either controlling or significant minority stakes in its investments, and also offers family office services including discretionary portfolio management and investment advisory. Isola is regulated by the Hong Kong Securities and Futures Commission.
Mezzofy is a global digital coupon and voucher platform that enables businesses to create, distribute, redeem, and manage digital coupons efficiently. The platform supports over 13,000 outlets worldwide and has processed more than 400 million coupons, representing over US$5 billion in value. Mezzofy offers a user-friendly experience, allowing merchants to launch unlimited marketing campaigns without requiring technical skills. For more advanced users, the platform provides integration capabilities with existing systems through an API, catering to the needs of both small and medium-sized enterprises as well as larger businesses. This comprehensive solution simplifies the coupon management process, making it accessible for all types of businesses.
Gense Technologies specializes in the development of an affordable and portable self-help medical imaging device designed for preventive screening and chronic disease monitoring. This innovative device allows users to perform self-administered imaging scans at home or in clinical settings, targeting early detection and management of prevalent diseases affecting the liver, lungs, and kidneys. Results are generated through an app using cloud-based machine learning algorithms, requiring no extensive training for users. Gense's team comprises 15 PhDs and researchers from prestigious institutions and is actively engaged in partnerships for clinical trials and engineering developments. The company has successfully raised over $3 million in funding and has achieved medical device certification, enabling mass production. Their devices are already in use in public hospitals, particularly for monitoring recovered COVID-19 patients, and Gense has attracted interest from healthcare distributors in more than 20 global markets, including private hospitals and health insurers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.